CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 407 enrolled
Drug / intervention
NeuroSAFE procedure +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03317990
NCT03317990N/AActive

A Single Blinded, IDEAL Stage 3, Multi-Centre, Randomised Controlled Trial to Assess NeuroSAFE Robotic Assisted Radical Prostatectomy (RARP) vs Standard Robotic Assisted Radical Prostatectomy (RARP) in Men With Prostate Cancer

University College, London·interventional·Posted Oct 23, 2017·Updated Sep 4, 2025

In Brief

A clinical study evaluating NeuroSAFE procedure and Standard RARP for Prostate Cancer. Active but no longer recruiting, targeting 407 participants across 5 sites.

Detailed Summary

In summary this trial will test whether this new surgical technique can be used to make surgery safer and more effective whilst allowing improved quality of life for patients having surgery for prostate cancer. If the technique is proven effective the investigators will use the experience gained to promote its use throughout the NHS through training courses and publication and dissemination of the resultant data. Staff from centres participating in this trial will be fully trained in the NeuroSAFE technique. A patient and public involvement afternoon was held for participants of the NeuroSAFE PROOF feasibility study, family members, men with prostate cancer, and staff members at UCLH. The event was supported by the charity Orchid Cancer appeal. The high levels of attendance was demonstrative of the support within our patient group for the work of this trial. The trial team listened to the comments made by participants and members of the public and have made some changes to the design of our trial as a result of this feedback.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited Kingdom

Timeline

N/AActive
20182019202020212022202320242025202620272028
First PostedOct 23, 2017
Enrollment StartApr 9, 2018
Primary CompletionApr 30, 2024
Study CompletionDec 1, 2027
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 8.7 years ago

Interventions

NeuroSAFE procedureprocedure

When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a significant positive margin (on more than one section from one side or in a single section but greater than or equal to 3mm) is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.

Standard RARPprocedure

Patients will undergo the standard intervention - RARP without NeuroSAFE Frozen section analysis